| Methods for cancer detection and monitoring B Zimmermann, R Salari, R Swenerton, HT Wu, H Sethi US Patent 12,024,738, 2024 | 44 | 2024 |
| Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection P Srinivasan, B Gutman, SL Bristow, HT Wu, R Salari, R Swenerton, ... CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 32 (12), 2023 | | 2023 |
| Abstract C119: Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection P Srinivasan, B Gutman, SL Bristow, HT Wu, R Salari, R Swenerton, ... Cancer Epidemiology, Biomarkers & Prevention 32 (12_Supplement), C119-C119, 2023 | | 2023 |
| Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay T Powles, A Young, H Nimeiri, RW Madison, A Fine, DR Zollinger, ... Frontiers in Oncology 13, 1221718, 2023 | 3 | 2023 |
| ctDNA detection before and during systemic therapy for inflammatory breast cancer. A Alexander, A Marx, J Wiley, M Kai, V Valero, WA Woodward, T Tin, ... Journal of Clinical Oncology 41 (16_suppl), e12523-e12523, 2023 | | 2023 |
| Abstract P040: Mutational heterogeneity of colorectal cancers across ancestries and its implications for cancer early detection P Srinivasan, B Gutman, V Aushev, S Sharma, T Arbel, HT Wu, ... Cancer Prevention Research 16 (1_Supplement), P040-P040, 2023 | | 2023 |
| Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer JY Hou, JS Chapman, E Kalashnikova, W Pierson, K Smith-McCune, ... Gynecologic Oncology 167 (2), 334-341, 2022 | 26 | 2022 |
| A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross, VN Aushev, HT Wu, ... Nature Cancer 3 (10), 1181-1191, 2022 | 54 | 2022 |
| Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: an exploratory analysis from the PREDATOR study of metastatic colorectal … S Lonardi, H Nimeiri, C Xu, DR Zollinger, RW Madison, AD Fine, ... International Journal of Molecular Sciences 23 (19), 11529, 2022 | 16 | 2022 |
| Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse F Cailleux, E Agostinetto, M Lambertini, F Rothé, HT Wu, M Balcioglu, ... JCO Precision Oncology 6, e2200148, 2022 | 32 | 2022 |
| Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant chemotherapy. MJM Magbanua, LB Swigart, D Renner, S Shchegrova, GL Hirst, C Yau, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| ctDNA prognosis in adjuvant triple-negative breast cancer L Molinero, D Renner, HT Wu, N Qi, R Patel, CW Chang, H Sethi, ... Cancer Research 82 (12_Supplement), 2796-2796, 2022 | 2 | 2022 |
| Abstract LB111: Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant … MJM Magbanua, LB Swigart, D Renner, S Shchegrova, GL Hirst, C Yau, ... Cancer Research 82 (12_Supplement), LB111-LB111, 2022 | | 2022 |
| Methods for cancer detection and monitoring B Zimmermann, R Salari, R Swenerton, HT Wu, H SETHI US Patent App. 17/461,298, 2022 | 23 | 2022 |
| Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor … A Young, H Nimeiri, R Madison, AD Fine, D Zollinger, O Gjoerup, ... Journal of Clinical Oncology 40 (6_suppl), 448-448, 2022 | 3 | 2022 |
| Detection of circulating tumor DNA post neoadjuvant chemotherapy using a personalized assay is associated with disease relapse E Agostinetto, F Cailleux, M Lambertini, F Rothe, HT Wu, M Balcioglu, ... Cancer Research 82 (4), 2022 | 1 | 2022 |
| Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery I Garcia-Murillas, RJ Cutts, L Ulrich, M Beaney, M Robert, M Coakley, ... Cancer Research 82 (4_Supplement), P2-01-10-P2-01-10, 2022 | 2 | 2022 |
| Abstract P2-01-06: Detection of circulating tumor DNA post neoadjuvant chemotherapy using a personalized assay is associated with disease relapse E Agostinetto, F Cailleux, M Lambertini, F Rothé, HT Wu, M Balcioglu, ... Cancer Research 82 (4_Supplement), P2-01-06-P2-01-06, 2022 | 1 | 2022 |
| Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal … H Nimeiri, A Young, R Madison, AD Fine, O Gjoerup, F Loupakis, ... Journal of Clinical Oncology 40 (4_suppl), 187-187, 2022 | 6 | 2022 |
| 1762P Association of clonal hematopoiesis of indeterminate potential with higher risk of disease progression D Klarin, E Kalashnikova, HT Wu, S Mehta, R Salari, H Sethi, ... Annals of Oncology 32, S1212, 2021 | | 2021 |
Ben RaphaelProfessor of Computer Science, Princeton UniversityVerified email at princeton.edu